Nachrichten zur Hims & Hers Health Aktie

Hims & Hers Health, Inc. (NYSE:HIMS) Sees Large Drop in Short Interest

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) was the recipient of a large decrease in short interest…

Is It Time To Reassess Hims & Hers Health (HIMS) After The Recent Share Price Surge

If you are wondering whether Hims & Hers Health at around US$26.99 is still offering value or already pricing in…

HIMS Receives Upgrade Amid Positive Regulatory Outlook

On April 17, 2026, Hims & Hers Health Inc (HIMS) received a Buy rating upgrade from Petri Dish Reports, highlighting…

+7.34% for Hims & Hers Health stock as FDA eyes peptide drug policy change

Hims & Hers Health trades at $28.97, up 7.34% today. Get the latest technicals, trends, and market outlook for HIMS.…

Hims & Hers stock jumps 14% after FDA schedules peptide compounding review

The FDA will convene an outside panel in July to weigh compounding eligibility for 7 peptides, a category Hims &…

Hims & Hers stock rises 14% as FDA schedules peptide compounding review

The U.S. Food and Drug Administration set July 23–24 advisory meetings to evaluate seven peptides for compounding eligibility, a development…

Hims & Hers Health (HIMS) Soars 11.1%: Is Further Upside Left in the Stock?

Hims & Hers Health (HIMS) saw its shares surge in the last session with trading volume being higher than average.…

Hims And Hers Peptide Review Adds New Angle To Valuation Debate

U.S. health authorities are reviewing peptide regulations, with a key FDA compounding advisory meeting scheduled for July.HHS communications, including comments…

Eli Lillys Oral Drug Clears CV Test, Hims Surges 14%

Eli Lillys oral obesity drug Foundayo passed cardiovascular safety testing while Hims & Hers surged 14% after the FDA scheduled…

Stock Market Today, April 16: Hims & Hers Health Jumps on FDA Review of Compounded Peptide Therapies

On April 16, 2026, investors monitored an FDA peptide review that could be a boost to Hims & Hers Health.…

HIMS Stock Rises 7% on Potential FDA Regulatory Changes

On April 16, 2026, Hims & Hers Health Inc (HIMS) saw its stock price increase by approximately 7% following statements…

Hims & Hers Health Stock Jumps as FDA Reconsiders Peptide Restrictions

Hims & Hers Health shares rose to $26.65 Thursday after the FDA said it would reconsider restrictions on several peptides,…

RFK Jr. Just Gave Hims & Hers Stock a Jolt. Should You Chase the Rally Here?

Hims & Hers stock rallies as RFK Jr. says FDA may remove restrictions on certain peptides. But HIMS shares remain…

Hims & Hers shares surge 8% on promising FDA peptide review

Hims & Hers stock jumped 8% after the FDA announced a formal review of wellness peptides for compounding, with Bank…

RFK Jr.s peptide policy could boost Hims & Hers as its GLP-1 business evolves

Hims may have an chance to grow peptides business as a potential revenue driver, with FDA review in 2026 shaping…

Hims & Hers: Der Befreiungsschlag steht bevor

Lange Zeit wurde die Aktie von Hims & Hers an der Börse fast ausschließlich als spekulatives Vehikel für den Hype…

Hims & Hers shares jump as FDA begins review of restricted peptide compounds

Shares of Hims & Hers Health (NYSE:HIMS) rose more than 8% to about $26 after the US Food and Drug…

HIMS Plunges 51.2% in 6 Months: Should You Still Hold the Stock or Sell?

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.…

Push to ease peptide restrictions positive for Hims & Hers, says Leerink

Leerink analyst Michael Cherny views Health and Human Services Secretary Robert Kennedy announcement that the FDA is seeking to remove…

Hims & Hers Health (HIMS) Jumps 6.6% to $26.03

Hims & Hers Health shares jumped 6.6% Thursday to $26.03 after B of A Securities boosted its price target by…

Hims & Hers stock extends gains as RFK Jr. signals FDA will consider looser restrictions on peptides

Hims & Hers stock jumped as RFK Jr. signaled that the FDA may ease restrictions on certain peptides.…

BofA Raises Hims & Hers Target to $25 as FDA Takes a Step Toward Wellness Peptides: Is a New Revenue Boom Coming?

Hims & Hers Health (NYSE:HIMS) just got a fresh look from Bank of America, which raised its price target on…

BofA Raises Hims & Hers Target to $25 as FDA Takes a Step Toward Wellness Peptides: Is a New Revenue Boom Coming?

Hims & Hers Health (NYSE:HIMS) just got a fresh look from Bank of America, which raised its price target on…

Market movers: Hims & Hers, Abbott Laboratories, QVC…

…

Hims & Hers stock rises 14% as FDA schedules peptide compounding review

The FDA will ask an outside panel to weigh whether 7 popular peptides can be produced by compounding pharmacies, opening…

Hims & Hers shares jump as FDA begins review of restricted peptide compounds

Shares of Hims & Hers Health (NYSE:HIMS) rose more than 8% to about $26 after the US Food and Drug Administration…

HIMS Stock Surges on FDAs Potential Regulatory Changes

On April 16, 2026, Hims & Hers Health Inc (HIMS) experienced a notable pre-market stock increase of 6.88%, following a…

FDA Peptide Review, A Big Moment For Hims & Hers (Rating Upgrade)

Hims & Hers faces key FDA decisions on compounded GLP-1/semaglutide peptides—upside if permitted, downside if restricted. Read my latest analysis…

Bank of America Issues Positive Forecast for Hims & Hers Health (NYSE:HIMS) Stock Price

Bank of America upped their price target on shares of Hims & Hers Health from $21.00 to $25.00 and gave…

Hims & Hers surges 4% as peptide policy shift unlocks growth

Hims & Hers surges 4% as peptide policy shift unlocks growth…

HIMS Maintained by B of A Securities -- Price Target Raised to $25

On October 03, 2023, Hims & Hers Health (HIMS) has received an updated rating from B of A Securities, led…

Hims & Hers (HIMS) Stock Jumps 13% as FDA Opens Door to Peptide Review

Hims & Hers (HIMS) stock surged 13% after the FDA scheduled peptide review meetings. BofA raised its price target to…

Why Is Hims & Hers Stock Soaring After FDAs Announcment? - Hims & Hers Health (NYSE:HIMS)

Hims & Hers stock rises as FDA plans to ease peptide therapy rules, opening new revenue opportunities and shifting regulatory…

Hims & Hers (HIMS) Shares Surge on FDA Peptide Regulation Update

On April 16, 2026, Hims & Hers Health Inc (HIMS) saw its stock rise by as much as 11% in…

HIMS Shares Surge 11% on FDA Regulatory News

On April 16, 2026, Hims & Hers Health Inc (HIMS) experienced an 11% increase in premarket trading, continuing its upward…

These stocks are today’s movers: TSMC, AMD, JB Hunt, Nvidia, Hims & Hers, and more

TSMC rises after the chip manufacturer’s earnings beat expectations, while Nvidia and AMD eye 12-day winning streaks.…

These Stocks Are Today’s Movers: TSMC, AMD, J.B. Hunt, Nvidia, Hims & Hers, and More

TSMC rises after the chip manufacturer’s earnings beat expectations, while Nvidia and AMD eye 12-day winning streaks.…

Hims & Hers on track to extend gains as RFK Jr. seeks to loosen peptide regulations

Hims & Hers stock jumps as FDA reviews easing peptide restrictions.…

Hims Jumps as RFK Jr. Seeks to Loosen Peptide Regulations

Hims & Hers Health Inc. surged as much as 12 percent after Health Secretary Robert F. Kennedy Jr. said US…

Hims & Hers shares rise 11% on FDA peptide restriction changes

Hims & Hers shares rise 11% on FDA peptide restriction changes…

Hims & Hers shares rise 11% on FDA peptide restriction changes

Hims & Hers shares rise 11% on FDA peptide restriction changes…

US Stocks Move: Hims & Hers rises over 7% as the FDA will review easing restrictions on peptide products

Glonghui April 16th | US internet healthcare company Hims & Hers Health rose over 7% to $26.02. According to reports,…

Q4 Earnings Outperformers: Hims & Hers Health (NYSE:HIMS) And The Rest Of The Healthcare Technology Stocks

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the healthcare technology stocks, including Hims &…

Hims & Hers Providers Cant Duck Suit Over Students Suicide

Medical providers for telehealth company Hims & Hers cant escape a wrongful death lawsuit from the family of a Washington…

Is Hims & Hers (HIMS) Using AI Upgrades To Cement A Durable Virtual Care Moat?

Hims & Hers Health recently announced that it would report its first-quarter 2026 results on May 11 and that management…

HIMS Plunges 51.2% in 6 Months: Should You Still Hold the Stock or Sell?

Hims & Hers rolls out Benefits and taps Novo Nordisk for GLP therapies in weight-loss care as revenue grows, but…

A Look at Hims & Hers Health Inc (HIMS) After 13.7% Gain -- GF Value $36.66 vs Price $24.29

On April 15, 2026, Hims & Hers Health Inc (HIMS) shares rose 13.7% to a current price of $24.29. This…

Investors Purchase Large Volume of Call Options on Hims & Hers Health (NYSE:HIMS)

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) was the target of unusually large options trading activity on…

BofA raises Hims and Hers stock price target on peptide optionality

BofA raises Hims and Hers stock price target on peptide optionality…

Hims & Hers stock jumps as U.S. moves forward with plan to reassess popular peptides

Hims & Hers Health’s plan to enter the business of selling peptides is looking a lot more realistic.…